Literature DB >> 12409506

Normal function of the cystic fibrosis conductance regulator protein can be associated with homozygous (Delta)F508 mutation.

Isabelle Sermet-Gaudelus1, Benoit Vallée, Ilse Urbin, Tania Torossi, Rémi Marianovski, Anne Fajac, Marie-Noëlle Feuillet, Jean-Louis Bresson, Gérard Lenoir, Jean François Bernaudin, Aleksander Edelman.   

Abstract

Cystic fibrosis (CF) is caused by mutations of the gene encoding for the CFTR (CF transmembrane conductance regulator) protein. The most frequent mutation, the (Delta)F508 mutation, results in a defective cAMP-regulated chloride transport in the epithelial cells. The spectrum of clinical manifestations in patients bearing homozygous (Delta)F508 mutations can vary considerably, suggesting that, in the patients with a mild disease, CFTR could be partly functional. To test this hypothesis, we explored in nasal ciliated epithelial cells (NCC) of 9 control subjects and 23 (Delta)F508 homozygous patients the anion conductive pathway by a halide sensitive fluorescent dye assay SPQ (6-methoxy-N-3'-sulfopropylquinolinium) and the CFTR transcript levels by RT-PCR. As 50% represented the lowest fraction of the control subjects NCC demonstrating a cAMP-dependent conductance, a CF patient was considered as "cAMP responder" if at least 50% of the NCC tested displayed a cAMP-dependent conductive pathway. According to these criteria, 8 of the 23 patients were considered as cAMP responders. They had a significantly less severe disease considering the respiratory function and infectious status. The amount of CFTR mRNA did not differ between the control subjects and the patients. No statistical correlation could be found between the transcript level and the expression of a cAMP conductive pathway. This cAMP-dependent Cl(-) conductance detected in homozygous NCC could be due to a residual CFTR activity and may explain the mild phenotypes observed in some (Delta)F508 homozygous patients.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12409506     DOI: 10.1203/00006450-200211000-00005

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  12 in total

1.  Exon skipping through the creation of a putative exonic splicing silencer as a consequence of the cystic fibrosis mutation R553X.

Authors:  Isabel Aznarez; Julian Zielenski; Johanna M Rommens; Benjamin J Blencowe; Lap-Chee Tsui
Journal:  J Med Genet       Date:  2007-05       Impact factor: 6.318

2.  Gene expression in transformed lymphocytes reveals variation in endomembrane and HLA pathways modifying cystic fibrosis pulmonary phenotypes.

Authors:  Wanda K O'Neal; Paul Gallins; Rhonda G Pace; Hong Dang; Whitney E Wolf; Lisa C Jones; XueLiang Guo; Yi-Hui Zhou; Vered Madar; Jinyan Huang; Liming Liang; Miriam F Moffatt; Garry R Cutting; Mitchell L Drumm; Johanna M Rommens; Lisa J Strug; Wei Sun; Jaclyn R Stonebraker; Fred A Wright; Michael R Knowles
Journal:  Am J Hum Genet       Date:  2015-01-29       Impact factor: 11.025

3.  Regulatory domain phosphorylation to distinguish the mechanistic basis underlying acute CFTR modulators.

Authors:  Louise C Pyle; Annette Ehrhardt; Lisa High Mitchell; Lijuan Fan; Aixia Ren; Anjaparavanda P Naren; Yao Li; J P Clancy; Graeme B Bolger; Eric J Sorscher; Steven M Rowe
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2011-07-01       Impact factor: 5.464

4.  Light and alcohol evoked electro-oculograms in cystic fibrosis.

Authors:  Paul A Constable; John G Lawrenson; Geoffrey B Arden
Journal:  Doc Ophthalmol       Date:  2006-10-05       Impact factor: 2.379

5.  Complete gene scanning by temperature gradient capillary electrophoresis using the cystic fibrosis transmembrane conductance regulator gene as a model.

Authors:  Lan-Szu Chou; Friederike Gedge; Elaine Lyon
Journal:  J Mol Diagn       Date:  2005-02       Impact factor: 5.568

6.  Suppression of CFTR premature termination codons and rescue of CFTR protein and function by the synthetic aminoglycoside NB54.

Authors:  Steven M Rowe; Peter Sloane; Li Ping Tang; Kyle Backer; Marina Mazur; Jessica Buckley-Lanier; Igor Nudelman; Valery Belakhov; Zsuzsa Bebok; Erik Schwiebert; Timor Baasov; David M Bedwell
Journal:  J Mol Med (Berl)       Date:  2011-07-22       Impact factor: 4.599

Review 7.  Cystic fibrosis transmembrane regulator protein mutations: 'class' opportunity for novel drug innovation.

Authors:  Kelvin D MacDonald; Karen R McKenzie; Pamela L Zeitlin
Journal:  Paediatr Drugs       Date:  2007       Impact factor: 3.022

8.  Elevated Mirc1/Mir17-92 cluster expression negatively regulates autophagy and CFTR (cystic fibrosis transmembrane conductance regulator) function in CF macrophages.

Authors:  Mia F Tazi; Duaa A Dakhlallah; Kyle Caution; Madelyn M Gerber; Sheng-Wei Chang; Hany Khalil; Benjamin T Kopp; Amr E Ahmed; Kathrin Krause; Ian Davis; Clay Marsh; Amy E Lovett-Racke; Larry S Schlesinger; Estelle Cormet-Boyaka; Amal O Amer
Journal:  Autophagy       Date:  2016-11       Impact factor: 16.016

9.  The CFTR frameshift mutation 3905insT and its effect at transcript and protein level.

Authors:  Javier Sanz; Thomas von Känel; Mircea Schneider; Bernhard Steiner; André Schaller; Sabina Gallati
Journal:  Eur J Hum Genet       Date:  2009-09-02       Impact factor: 4.246

10.  The ΔF508 mutation causes CFTR misprocessing and cystic fibrosis-like disease in pigs.

Authors:  Lynda S Ostedgaard; David K Meyerholz; Jeng-Haur Chen; Alejandro A Pezzulo; Philip H Karp; Tatiana Rokhlina; Sarah E Ernst; Robert A Hanfland; Leah R Reznikov; Paula S Ludwig; Mark P Rogan; Greg J Davis; Cassie L Dohrn; Christine Wohlford-Lenane; Peter J Taft; Michael V Rector; Emma Hornick; Boulos S Nassar; Melissa Samuel; Yuping Zhang; Sandra S Richter; Aliye Uc; Joel Shilyansky; Randall S Prather; Paul B McCray; Joseph Zabner; Michael J Welsh; David A Stoltz
Journal:  Sci Transl Med       Date:  2011-03-16       Impact factor: 17.956

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.